NewAmsterdam Pharma (NAMS) News Today → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free NAMS Stock Alerts $19.30 -0.30 (-1.53%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 9 at 3:56 AM | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from BrokeragesJune 8 at 5:52 AM | americanbankingnews.comNewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of CanadaJune 7 at 4:01 PM | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 7 at 11:14 AM | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for NewAmsterdam Pharma (NASDAQ:NAMS)Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Friday.May 30, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Significant Decline in Short InterestNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 274,600 shares, a decline of 26.8% from the April 30th total of 375,000 shares. Based on an average daily volume of 180,500 shares, the short-interest ratio is presently 1.5 days. Currently, 0.4% of the shares of the stock are sold short.May 29, 2024 | finance.yahoo.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneMay 21, 2024 | finance.yahoo.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsMay 17, 2024 | investing.comNewAmsterdam Pharma stock initiated with Buy rating by TD CowenMay 17, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)May 16, 2024 | msn.comTD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationMay 15, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12-month pricMay 10, 2024 | finance.yahoo.comNewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)May 9, 2024 | globenewswire.comNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsMay 3, 2024 | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | finance.yahoo.comNewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024April 30, 2024 | bloomberg.comOzempic Maker Novo Nordisk Has Denmark’s Economy HookedApril 30, 2024 | msn.comFTC challenges ‘junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicApril 23, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 6.7% Higher NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 6.7%April 16, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 2.6%NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 2.6%April 10, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 2.1%NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 2.1%April 9, 2024 | businesswire.comBioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of DirectorsApril 9, 2024 | globenewswire.comNewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseApril 8, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 4.9%April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)April 1, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading VolumeNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseApril 1, 2024 | globenewswire.comNewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerMarch 29, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $181,223.50 in StockMarch 29, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $4,095,234.00 in StockMarch 28, 2024 | msn.comIf you loved NBC's ER, this new Max medical drama is the show for youMarch 28, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $181,223.50 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 8,429 shares of the company's stock in a transaction on Tuesday, March 26th. The shares were bought at an average cost of $21.50 per share, with a total value of $181,223.50. Following the acquisition, the director now directly owns 3,008,429 shares in the company, valued at $64,681,223.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.March 27, 2024 | marketbeat.comJohannes Jacob Piete Kastelein Sells 190,476 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 190,476 shares of the company's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $21.50, for a total transaction of $4,095,234.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 26, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading VolumeNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading VolumeMarch 25, 2024 | globenewswire.comNewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressMarch 19, 2024 | seekingalpha.comNAMS NewAmsterdam Pharma Company N.V.March 14, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Recommendation of "Buy" by AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have received an average recommendation of "Buy" from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-monthMarch 14, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Research Coverage Started at ScotiabankScotiabank started coverage on shares of NewAmsterdam Pharma in a report on Thursday. They issued a "sector outperform" rating and a $35.00 price objective for the company.March 13, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 3.1%NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 3.1%March 13, 2024 | msn.comAmring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic AcquisitionMarch 12, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading VolumeMarch 12, 2024 | globenewswire.comNewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDMarch 1, 2024 | finance.yahoo.comNewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss ExpectationsMarch 1, 2024 | marketbeat.comEquities Analysts Set Expectations for NewAmsterdam Pharma's Q3 2025 Earnings (NASDAQ:NAMS)NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities researchers at William Blair issued their Q3 2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a research report issued on Wednesday, February 28th. William Blair analyst M. Phipps expects that the company will post earniFebruary 28, 2024 | finanznachrichten.deNewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | finance.yahoo.comNewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical ProgressFebruary 28, 2024 | globenewswire.comNewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for NewAmsterdam Pharma with Increased Price Target Amid Promising Drug Trials and Strategic InitiativesFebruary 26, 2024 | finance.yahoo.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchFebruary 24, 2024 | msn.comNewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11February 23, 2024 | benzinga.comNewAmsterdam Pharma Stock (NASDAQ:NAMS), Insider Trading ActivityFebruary 20, 2024 | msn.comList of Universities that offer pharmacy in South Africa in 2024 Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution NAMS Media Mentions By Week NAMS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.320.76▲Average Medical News Sentiment NAMS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼51▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Jazz Pharmaceuticals News Blueprint Medicines News Viking Therapeutics News Ionis Pharmaceuticals News Organon & Co. News Madrigal Pharmaceuticals News Summit Therapeutics News BridgeBio Pharma News Cytokinetics News Apellis Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored